1 Kaufman, P. L., Gabelt, B. T. & Cynader, M. Introductory comments on neuroprotection. Survey of ophthalmology 43 Suppl 1, S89-90 (1999).
2 Wiederholt, M., Bielka, S., Schweig, F., Lutjen-Drecoll, E. & Lepple-Wienhues, A. Regulation of outflow rate and resistance in the perfused anterior segment of the bovine eye. Exp Eye Res 61, 223-234 (1995).
3 Gabelt, B. T. & Kaufman, P. L. Changes in aqueous humor dynamics with age and glaucoma. Progress in retinal and eye research 24, 612-637, doi:10.1016/j.preteyeres.2004.10.003 (2005).
4 Grant, W. M. Experimental aqueous perfusion in enucleated human eyes. Archives of ophthalmology (Chicago, Ill. : 1960) 69, 783-801 (1963).
5 Rosenquist, R., Epstein, D., Melamed, S., Johnson, M. & Grant, W. M. Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy. Current eye research 8, 1233-1240 (1989).
6 Maepea, O. & Bill, A. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp Eye Res 54, 879-883 (1992).
7 Johnson, M., Shapiro, A., Ethier, C. R. & Kamm, R. D. Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci 33, 1670-1675 (1992).
8 Vranka, J. A., Kelley, M. J., Acott, T. S. & Keller, K. E. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Exp Eye Res 133, 112-125, doi:10.1016/j.exer.2014.07.014 (2015).
9 Torrejon, K. Y. et al. TGFbeta2-induced outflow alterations in a bioengineered trabecular meshwork are offset by a rho-associated kinase inhibitor. Scientific reports 6, 38319, doi:10.1038/srep38319 (2016).
10 Quigley, H. A. Open-angle glaucoma. The New England journal of medicine 328, 1097-1106, doi:10.1056/nejm199304153281507 (1993).
11 Saeki, T., Ota, T., Aihara, M. & Araie, M. Effects of prostanoid EP agonists on mouse intraocular pressure. Invest Ophthalmol Vis Sci 50, 2201-2208, doi:10.1167/iovs.08-2800 (2009).
12 Honjo, M. et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 42, 137-144 (2001).
13 Honjo, M. & Tanihara, H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Japanese journal of ophthalmology, doi:10.1007/s10384-018-0566-9 (2018).
14 Umezu-Goto, M. et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of cell biology 158, 227-233, doi:10.1083/jcb.200204026 (2002).
15 Tokumura, A. et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. The Journal of biological chemistry 277, 39436-39442, doi:10.1074/jbc.M205623200 (2002).
16 van Meeteren, L. A. & Moolenaar, W. H. Regulation and biological activities of the autotaxin-LPA axis. Progress in lipid research 46, 145-160, doi:10.1016/j.plipres.2007.02.001 (2007).
17 Nakanaga, K., Hama, K. & Aoki, J. Autotaxin--an LPA producing enzyme with diverse functions. Journal of biochemistry 148, 13-24, doi:10.1093/jb/mvq052 (2010).
18 Saga, H. et al. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS One 9, e93230, doi:10.1371/journal.pone.0093230 (2014).
19 Benesch, M. G. et al. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J 28, 2655-2666, doi:10.1096/fj.13-248641 (2014).
20 Honjo, M. et al. Autotaxin-Lysophosphatidic Acid Pathway in Intraocular Pressure Regulation and Glaucoma Subtypes. Invest Ophthalmol Vis Sci 59, 693- 701, doi:10.1167/iovs.17-23218 (2018).
21 Rao, P. V. Bioactive lysophospholipids: role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 30, 181-190, doi:10.1089/jop.2013.0194 (2014).
22 Kawaguchi, M. et al. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem Biol 8, 1713-1721, doi:10.1021/cb400150c (2013).
23 Srinivasan, B. et al. TEER measurement techniques for in vitro barrier model systems. Journal of laboratory automation 20, 107-126, doi:10.1177/2211068214561025 (2015).
24 Hartsock, A. & Nelson, W. J. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochimica et biophysica acta 1778, 660-669, doi:10.1016/j.bbamem.2007.07.012 (2008).
25 Zhang, H. et al. Dual activity lysophosphatidic acid receptor pan- antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer research 69, 5441-5449, doi:10.1158/0008-5472.Can-09-0302 (2009).
26 Ferry, G. et al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 327, 809-819, doi:10.1124/jpet.108.141911 (2008).
27 Park, G. Y. et al. Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. American journal of respiratory and critical care medicine 188, 928-940, doi:10.1164/rccm.201306-1014OC (2013).
28 Oikonomou, N. et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. American journal of respiratory cell and molecular biology 47, 566-574, doi:10.1165/rcmb.2012-0004OC (2012).
29 Albers, H. M. et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. U. S. A. 107, 7257-7262, doi:10.1073/pnas.1001529107 (2010).
30 Gierse, J. et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther 334, 310-317, doi:10.1124/jpet.110.165845 (2010).
31 Iyer, P. et al. Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS One 7, e42627, doi:10.1371/journal.pone.0042627 (2012).
32 Nagano, T. et al. Vol. U.S. patent, No.20160002247A1 (2016).
33 Bean, G. W. & Camras, C. B. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Survey of ophthalmology 53 Suppl1, S69-84, doi:10.1016/j.survophthal.2008.08.012 (2008).
34 Krupa, M., Chodynski, M., Ostaszewska, A., Cmoch, P. & Dams, I. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost. Molecules (Basel, Switzerland) 22, doi:10.3390/molecules22020217 (2017).
35 Bito, L. Z. & Baroody, R. A. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp Eye Res 44, 217-226 (1987).
36 Takagi, Y. et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78, 767-776, doi:10.1016/j.exer.2003.12.007 (2004).
37 Zawilska, J. B., Wojcieszak, J. & Olejniczak, A. B. Prodrugs: a challenge for the drug development. Pharmacological reports : PR 65, 1-14 (2013).
38 Patel, A., Cholkar, K., Agrahari, V. & Mitra, A. K. Ocular drug delivery systems: An overview. World journal of pharmacology 2, 47-64, doi:10.5497/wjp.v2.i2.47 (2013).
39 Gaudana, R., Ananthula, H. K., Parenky, A. & Mitra, A. K. Ocular drug delivery. The AAPS journal 12, 348-360, doi:10.1208/s12248-010-9183-3 (2010).
40 Nishimasu, H. et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nature structural & molecular biology 18, 205-212, doi:10.1038/nsmb.1998 (2011).
41 Hausmann, J. et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nature structural & molecular biology 18, 198-204, doi:10.1038/nsmb.1980 (2011).
42 Wildman, S. A. & Crippen, G. M. Prediction of Physicochemical Parameters by Atomic Contributions. Journal of Chemical Information and Computer Sciences 39, 868-873, doi:10.1021/ci990307l (1999).
43 Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular screening 4, 67-73, doi:10.1177/108705719900400206 (1999).
44 Eom, Y. et al. The effects of proinflammatory cytokines on the apoptosis of corneal endothelial cells following argon laser iridotomy. Exp Eye Res 145, 140- 147, doi:10.1016/j.exer.2015.11.022 (2016).
45 Yun, H. et al. A laser-induced mouse model with long-term intraocular pressure elevation. PLoS One 9, e107446, doi:10.1371/journal.pone.0107446 (2014).
46 Fu, C. T. & Sretavan, D. Laser-induced ocular hypertension in albino CD-1 mice. Invest Ophthalmol Vis Sci 51, 980-990, doi:10.1167/iovs.09-4324 (2010).
47 Srinivasan, K. et al. Comparison of New Visual Disturbances after Superior versus Nasal/Temporal Laser Peripheral Iridotomy: A Prospective Randomized Trial. Ophthalmology, doi:10.1016/j.ophtha.2017.09.015 (2017).
48 Kim, Y. Y. & Lee, T. S. Biphasic intraocular pressure response to laser irradiation of the iris in rabbits. Ophthalmic research 27, 243-248, doi:10.1159/000267712 (1995).
49 Aihara, M., Lindsey, J. D. & Weinreb, R. N. Experimental mouse ocular hypertension: establishment of the model. Invest Ophthalmol Vis Sci 44, 4314- 4320 (2003).
50 Nakamura, K. et al. Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clinical biochemistry 40, 274-277, doi:10.1016/j.clinbiochem.2006.10.009 (2007).
51 Pattabiraman, P. P., Maddala, R. & Rao, P. V. Regulation of plasticity and fibrogenic activity of trabecular meshwork cells by Rho GTPase signaling. Journal of cellular physiology 229, 927-942, doi:10.1002/jcp.24524 (2014).
52 Underwood, J. L. et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. The American journal of physiology 277, C330-342 (1999).
53 Alvarado, J. A., Betanzos, A., Franse-Carman, L., Chen, J. & Gonzalez-Mariscal, L. Endothelia of Schlemm's canal and trabecular meshwork: distinct molecular, functional, and anatomic features. Am J Physiol Cell Physiol 286, C621-634, doi:10.1152/ajpcell.00108.2003 (2004).
54 Yukiura, H. et al. Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish. The Journal of biological chemistry 286, 43972-43983, doi:10.1074/jbc.M111.301093 (2011).